Chairman and Chief Executive Officer of Pfizer, Albert Bourla, last week said that people will “likely” need a third dose of his company’s COVID-19 shot within six to 12 months of vaccination.
Speaking during a CVS Health Live event, Bourla said that new data shows that Pfizer's vaccine is effective against a concerning variant of the coronavirus that was first seen in South Africa.
“A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed,” he said, adding that variants will play a “key role”.
“It is extremely important to suppress the pool of people that can be susceptible to the virus.”
Researchers currently do not know how long vaccines provide protection against the coronavirus.
The Greek CEO also defended the price of his company’s vaccine, saying they are saving lives and will not be sold to poor countries for a profit.
“Vaccines are very expensive...They save human lives, they allow economies to reopen but we sell them at the price of a meal."
*More on GCT: Pfizer seeking Greek specialists for their new Digital Technology Hub in Thessaloniki
